ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

Key Points

• ProQR Therapeutics is expected to report Q3 2026 results before the market opens on November 5, with analysts forecasting a loss of $0.11 per share and revenue of $4.30 million.
• In its previous quarter, ProQR reported a $0.09-per-share loss, outperforming the $0.13 consensus loss estimate, while revenue reached $10.0 million versus expectations of $4.56 million.
• Analyst sentiment is moderately positive, with six Buy ratings, one Hold and one Sell; the average price target is $7.60, compared with the stock’s recent price of $1.41.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.11) per share and revenue of $4.30 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. The company had revenue of $10.00 million during the quarter, compared to analysts' expectations of $4.56 million. On average, analysts expect ProQR Therapeutics to post ($0.45) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

ProQR Therapeutics Stock Performance

Shares of PRQR stock opened at $1.41 on Thursday. ProQR Therapeutics has a 52-week low of $1.20 and a 52-week high of $2.84. The stock has a market cap of $148.56 million, a PE ratio of -3.07 and a beta of 0.20. The firm's 50 day moving average price is $1.79 and its two-hundred day moving average price is $1.70.

Analysts Set New Price Targets

A number of brokerages recently commented on PRQR. Weiss Ratings raised ProQR Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 14th. Chardan Capital reissued a "buy" rating and issued a $3.00 target price on shares of ProQR Therapeutics in a research note on Thursday, October 1st. HC Wainwright reduced their target price on ProQR Therapeutics to $8.00 and set a "buy" rating on the stock in a report on Thursday, October 1st. Wall Street Zen raised ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, Citigroup reiterated a "market outperform" rating on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $7.60.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA.

ProQR's research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR serves the global biotechnology and pharmaceutical markets through its research, development and strategic collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.